Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial

DSpace Repository

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial

Author: Herrlinger, Ulrich; Tzaridis, Theophilos; Mack, Frederic; Steinbach, Joachim Peter; Schlegel, Uwe; Sabel, Michael; Hau, Peter; Kortmann, Rolf-Dieter; Krex, Dietmar; Grauer, Oliver; Goldbrunner, Roland; Schnell, Oliver; Baehr, Oliver; Uhl, Martin; Seidel, Clemens; Tabatabai, Ghazaleh; Kowalski, Thomas; Ringel, Florian; Schmidt-Graf, Friederike; Suchorska, Bogdana; Brehmer, Stefanie; Weyerbrock, Astrid; Renovanz, Miriam; Bullinger, Lars; Galldiks, Norbert; Vajkoczy, Peter; Misch, Martin; Vatter, Hartmut; Stuplich, Moritz; Schaefer, Niklas; Kebir, Sied; Weller, Johannes; Schaub, Christina; Stummer, Walter; Tonn, Joerg-Christian; Simon, Matthias; Keil, Vera C.; Nelles, Michael; Urbach, Horst; Coenen, Martin; Wick, Wolfgang; Weller, Michael; Fimmers, Rolf; Schmid, Matthias; Hattingen, Elke; Pietsch, Torsten; Coch, Christoph; Glas, Martin
Tübinger Autor(en):
Tabatabai, Ghazaleh
Published in: Lancet (2019), Bd. 393, H. 10172, S. 678-688
Verlagsangabe: Elsevier Science Inc
Language: English
Full text: http://dx.doi.org/10.1016/S0140-6736(18)31791-4
ISSN: 1474-547X
DDC Classifikation: 610 - Medicine and health
Dokumentart: Artikel
Show full item record

This item appears in the following Collection(s)